SCHEMBL1015904

SCHEMBL1015904

COC(=O)c1cc(Cl)ccc1NC(=O)CCCC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
POLB P06746 2/20 0.54
KDM4E B2RXH2 6/20 0.53
TDP1 Q9NUW8 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HSD17B10 Q99714 2/20 0.52
HPGD P15428 1/20 0.52
KMT2A Q03164 2/20 0.52
MAPT P10636 2/20 0.52
MEN1 O00255 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
GAA P10253 3/20 0.50
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50
RXFP1 Q9HBX9 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9194516 0.88 ALDH1A1 (0.64) ALDH1A1POLBKDM4EKMT2AMAPT
Hydrochloric Acid SCHEMBL420699 0.86 RXFP1 (0.48) ALDH1A1POLBKDM4ESMN1; SMN2HPGD
SCHEMBL1797245 0.86 ALDH1A1 (0.52) ALDH1A1POLBKDM4EKMT2AMAPT
SCHEMBL417874 0.82 RXFP1 (0.54) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL1015370 0.82 KDM4E (0.60) ALDH1A1POLBKDM4ESMN1; SMN2HSD17B10
Trifluoroacetic Acid SCHEMBL1798236 0.81 KDM4E (0.45) ALDH1A1POLBKDM4ESMN1; SMN2KMT2A
SCHEMBL9674267 0.81 ALDH1A1 (0.65) ALDH1A1POLBKDM4ESMN1; SMN2HSD17B10
SCHEMBL30044907 0.81 KMT2A (0.63) ALDH1A1POLBKDM4ESMN1; SMN2HSD17B10
SCHEMBL6510154 0.81 KMT2A (0.63) ALDH1A1POLBKDM4ESMN1; SMN2HSD17B10
SCHEMBL30556513 0.81 RXFP1 (0.53) ALDH1A1POLBKDM4ESMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 ALDH1A1 888/4885POLB 2992/4885KDM4E 4108/4885
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 ALDH1A1 800/4885POLB 2674/4885KDM4E 4309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.